Mendus AB: Mendus to participate in upcoming conferences in September

Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell-based immunotherapies, today announced its participation in the following upcoming conferences:

LSX Nordic Congress 2022

Copenhagen, Denmark, September 6-7, 2022

Mendus CEO Erik Manting will present on September 6^th, 2022, at 3:30 pm CET as part of the "Investable-Showcase" track.

https://www.lsxleaders.com/lsx-nordic-congress

Pareto Securities' 13th Annual Healthcare Conference

Stockholm, Sweden, September 7-8, 2022

Mendus CEO Erik Manting will present on September 8^th, 2022, at 2:30 pm CET.

https://paretosec.com/updates/events-and-conferences/

Sachs 22^nd Annual Biotech in Europe Forum

Basel, Switzerland, September 21-22, 2022

Mendus CEO Erik Manting will participate in the "Immuno-Oncology BD & Partnering" panel discussion on Wednesday, 21st of September.

https://www.sachsforum.com/22bef-about.html

HollandBIO and Oncode Institute's"Next Frontiers in Cancer Vaccines"Event

Amsterdam, The Netherlands, September 28, 2022

Mendus CEO Erik Manting will present at 3:10 pm CET.

https://www.hollandbio.nl/event/biotech-wednesday-next-frontiers-in-cancer-vaccines-2/

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: [e-mail]

INVESTOR RELATIONS

Julie Seidel

Stern Investor Relations

Telephone: [phone]

E-mail: [e-mail]

MEDIA RELATIONS

Mario Brkulj

Valency Communications

Telephone: [phone]

E-mail: [e-mail]

ABOUT MENDUS AB

Attachment

• 220901_Mendus_Conferences_Sep_2022_ENG (https://ml-eu.globenewswire.com/Resource/Download/25aa350a-e69e-4542-9b3f-df94f7a26bb2)